Kozell L B, Machida C A, Neve R L, Neve K A
Veterans Affairs Medical Center, Portland, Oregon 97201.
J Biol Chem. 1994 Dec 2;269(48):30299-306.
D1/D2 chimeras were constructed that had D1 dopamine receptor sequence at the amino-terminal end and D2 dopamine receptor sequence at the carboxyl-terminal end. The chimeras with the first four, five and six transmembrane domains of the D1 receptor (CH2, CH3, CH4, respectively) bound the D1 receptor antagonist [3H]SCH 23390 with high affinity. Reciprocal chimeras constructed with D2 receptor sequence at the amino-terminal end displayed no detectable specific binding of [3H]SCH 23390, [125I]epidepride, or [3H]spiperone. CH2, CH3, and CH4 had lower affinity than either D1 or D2 dopamine receptors for the nonselective antagonists and agonists and D2-selective antagonists tested. The chimeric receptors had affinities for three D1-selective ligands and the D2-selective agonist, quinpirole, that were intermediate between D1 and D2 receptor affinities for the drugs. The substantial loss or gain of affinity for three ligands upon replacement of D1 transmembrane VII with D2 sequence (CH4) suggests an important role for this region in the selectivity of these drugs. Stimulation of adenylyl cyclase activity by D1 agonists occurred in cells expressing CH3 and CH4, both of which included the D1 third cytoplasmic loop, but not in cells expressing CH1 or CH2, both with the D2 third cytoplasmic loop. However, only CH3 was able to mediate stimulation of adenylyl cyclase by quinpirole, implying that D2 receptor transmembrane domain VI was an important determinant of the selective efficacy of quinpirole. On the other hand, transmembrane domain VII was particularly important for the selective potency of quinpirole. Inhibition of beta-adrenergic receptor-stimulated adenylyl cyclase activity by dopamine was seen in cells expressing D2 receptors and CH1, but not CH2, CH3, or CH4. Thus, the third cytoplasmic loop of D1 dopamine receptors was crucial for the coupling of the receptors to Gs, but inhibition of adenylyl cyclase via Gi required structural features, such as the second cytoplasmic loop of the D2 receptor, in addition to the 3rd cytoplasmic loop.
构建了D1/D2嵌合体,其氨基末端具有D1多巴胺受体序列,羧基末端具有D2多巴胺受体序列。具有D1受体前四个、五个和六个跨膜结构域的嵌合体(分别为CH2、CH3、CH4)与D1受体拮抗剂[3H]SCH 23390具有高亲和力结合。在氨基末端用D2受体序列构建的反向嵌合体未显示出可检测到的[3H]SCH 23390、[125I]表哌啶或[3H]螺哌隆的特异性结合。CH2、CH3和CH4对非选择性拮抗剂、激动剂以及所测试的D2选择性拮抗剂的亲和力低于D1或D2多巴胺受体。嵌合受体对三种D1选择性配体和D2选择性激动剂喹吡罗的亲和力介于D1和D2受体对这些药物的亲和力之间。用D2序列(CH4)替换D1跨膜结构域VII后,对三种配体的亲和力大幅丧失或增加,表明该区域在这些药物的选择性中起重要作用。D1激动剂对腺苷酸环化酶活性的刺激发生在表达CH3和CH4的细胞中,这两者都包含D1第三胞质环,但在表达CH1或CH2的细胞中未发生,这两者都具有D2第三胞质环。然而,只有CH3能够介导喹吡罗对腺苷酸环化酶的刺激,这意味着D2受体跨膜结构域VI是喹吡罗选择性效能的重要决定因素。另一方面,跨膜结构域VII对喹吡罗的选择性效力尤为重要。在表达D2受体和CH1的细胞中观察到多巴胺对β-肾上腺素能受体刺激的腺苷酸环化酶活性的抑制,但在CH2、CH3或CH4中未观察到。因此,D1多巴胺受体的第三胞质环对于受体与Gs的偶联至关重要,但通过Gi对腺苷酸环化酶的抑制除了第三胞质环外还需要结构特征,如D2受体的第二胞质环。